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Introduction {#sec001}
============

Cardiovascular function is central to the health of pediatric patients with congenital and acquired heart disease, but the ability to accurately assess cardiac hemodynamics rapidly in a non-invasive manner is limited \[[@pone.0227145.ref001]\]. Echocardiography is currently the standard for non-invasive evaluation of left ventricular (LV) function in the pediatric population \[[@pone.0227145.ref002]\]. LV function is typically assessed by linear (M-mode) or two-dimensional echocardiographic indices such as the modified Simpson method or 5/6 area-length method \[[@pone.0227145.ref003]--[@pone.0227145.ref005]\]. Technical issues such as inadequate image quality and measurement variability based on assumptions that a single plane accurately represents a normally shaped ellipsoidal LV limit these methods \[[@pone.0227145.ref006]--[@pone.0227145.ref008]\]. Additionally, there is significant inter- and intra-observer variability in evaluation of LV function measures such as LV ejection fraction (LVEF) \[[@pone.0227145.ref009]\]. An echocardiogram requires time, specialized equipment, and health professionals trained in pediatric cardiology to perform and interpret the study, limiting assessment of ventricular function in pediatric patients to inpatient and outpatient centers specialized in pediatric cardiology. Other methods which are more accurate in measuring LV function such as 3D echocardiogram \[[@pone.0227145.ref010]\] and cardiac MRI \[[@pone.0227145.ref011]\] are even more limited in terms of accessibility, time intensiveness, and cost. A cardiac MRI can pose additional risks if anesthesia is required, as can occur in the case of infants and young children. Therefore, there remains a need for a non-invasive, inexpensive, and easy to use device for the diagnosis and monitoring of cardiovascular health in the pediatric population.

Pahlevan et. al \[[@pone.0227145.ref012]\] recently introduced a new mathematical method, called the intrinsic frequency (IF) method, that is suitable for the dynamic analysis of coupled physiological systems such as the LV and the arterial network. IF uses an integrative systems approach that considers the LV and arterial network as a coupled dynamical system (LV + arterial tree) that is decoupled upon closure of the aortic valve \[[@pone.0227145.ref013]--[@pone.0227145.ref016]\]. Previous clinical studies have shown that the IF method can be used to estimate LVEF from non-invasive arterial waveforms measured by an iPhone \[[@pone.0227145.ref017]\]. Recently, a wireless handheld prototype device (Vivio) capable of simultaneous collection of arterial pulse waveform and phonocardiogram data from the carotid artery was proven to accurately estimate LVEF using the IF method in a large study of adult patients with anthracycline exposure secondary to treatment of childhood cancer \[[@pone.0227145.ref018]\]. The Vivio requires little time as well as minimal training for use and was shown to measure LVEF more accurately than echocardiogram, with results comparable to the gold standard of cardiac MRI \[[@pone.0227145.ref018]\]. Given the range of neck sizes within the pediatric population, the Vivio was modified in this study to create both a smaller device head to fit more easily in small necks as well as a larger but more sensitive device to help reduce the amount of hand pressure required to collect a pulse signal.

This study explores whether the Vivio can be utilized in collecting carotid pressure waveforms and computing IFs in a pediatric population. The objectives of this study are to 1) evaluate whether the Vivio can be used to collect carotid artery waveforms required for IF calculations in patients ages 0 to 19 years; 2) compare the performance of two different sensor head geometries, one larger and one smaller, in a pediatric population to the standard sensor head size \[[@pone.0227145.ref018]\]; and 3) compare the range of intrinsic frequencies derived from the Vivio between different pediatric age groups and between children and adults with normal LV function.

Materials and methods {#sec002}
=====================

Study participants {#sec003}
------------------

A clinical study was conducted at Children's Hospital Los Angeles (CHLA). The Children's Hospital Los Angeles Institutional Review Board (IRB) approved the study protocol and informed consent was obtained from the participants and/or legal guardians. Patients aged 0--19.9 years cared for at the CHLA Cardiology Clinic were invited to participate if an echocardiogram determined they had normal cardiac anatomy and ventricular function. This included post-cardiac transplant patients (n = 6) and post-chemotherapy patients with normal function on prior echocardiograms (n = 8). Exclusion criteria included patients with congenital heart disease or heart failure. A population of 28 adults ages 20--50 years with normal cardiac function and IFs collected from a prior IRB-approved study served as the comparison group \[[@pone.0227145.ref017]\].

Standard cardiac evaluation: Echocardiogram {#sec004}
-------------------------------------------

All echocardiographic studies were performed at CHLA using either an IE33 or Epiq 7 ultrasound system (Philips, Amsterdam, Netherlands). Images required for analysis included M-mode and 2D in the parasternal short axis at the mid-papillary muscle level of the LV, and 2D four-chamber view. Echocardiographic assessments were performed according to American Society of Echocardiogram guidelines. LV function was evaluated by measuring shortening fraction (FS) and ejection fraction (EF). FS was calculated from the LV end diastolic diameter (LVEDD) and LV end systolic diameter (LVESD) measurements in M-mode as: FS = 100\*(LVEDD-LVEDS)/LVEDD. An IntelliSpace Cardiovascular Workstation (Philips), in apical 4-chamber view was used to calculate end-systolic and end-diastolic volumes using the modified Simpson's method. LV volumes were also measured via the 5/6 area-length method using the parasternal short axis view for area and apical four-chamber view for length. Using this method, LV volume was calculated at end-diastole and end-systole as: 5/6 \* cross sectional area \* length. LVEF percentage was calculated using the volumes derived from the modified Simpsons and 5/6 area-length method as: LVEF = 100\*(LV end diastolic volume--LV end systolic volume)/(LV end diastolic volume) \[[@pone.0227145.ref004], [@pone.0227145.ref005]\]. LV volume calculations were performed by a single study investigator (J.M.).

Wireless handheld device: Vivio {#sec005}
-------------------------------

The Vivio operates like an optical tonometer that captures the carotid arterial waveform by recording the vibrations of the skin due to the pulse pressure wave as it propagates through the underlying vessel (e.g. carotid artery). The device uses a photoreflector that faces a reflective membrane which removes any variability in optical response to changes in skin tone. The Vivio was designed to address some of the shortcomings of conventional tonometry such as the requirement to have a rigid structure supporting the artery during measurement as well as probe perpendicularity. The incorporation of a membrane versus a probe tip affords the user greater freedom in the placement of the device over the pulse, which makes the carotid pulse measurement easier in pediatric patients. The Vivio system can be used with any mobile device or smartphone platform and therefore is inexpensive to deploy.

To better understand the effect of Vivio head geometry on the quality on carotid pulse waveforms collected in a pediatric population, three different head geometries were tested. The standard head size (inner diameter (ID) = 25 mm, outer diameter (OD) 30 mm) was the same as the adult version of the device used in previous studies \[[@pone.0227145.ref018]\]. Since the Vivio is a membrane-based tonometer there are two options to facilitate Vivio measurements in a pediatric population. One is to increase the size of the head, effectively lowering the membrane stiffness and reducing the pressure required to capture a carotid artery signal. The other is to decrease the geometry of the head to better accommodate the pediatric anatomy at the cost of increased pressure to capture a carotid artery signal due to increase membrane stiffness. For the smaller head, the ID was adjusted to 20 mm and the OD to 25 mm. For the larger head, the ID was adjusted to 30 mm and the OD to 35 mm. [Fig 1](#pone.0227145.g001){ref-type="fig"} shows the device as well as the small, standard, and large heads. Adhesive contact thickness (difference in OD---ID = 5 mm) was kept the same in all heads.

![Device design and Vivo head modifications.\
Vivio device with an example and schematic of a large (A) and standard (B) head. (C). From left to right, comparison of the small (ID 20mm, OD 25 mm), standard (ID 25mm, OD 30 mm), and large heads (ID 30mm, OD 35mm). Abbr: Inner diameter (ID); outer diameter (OD).](pone.0227145.g001){#pone.0227145.g001}

The carotid pulse waveform of patients was recorded using the Vivio by gently holding the device against the neck of the subject over the carotid pulse for at least one minute. The data was transmitted via Bluetooth to an iPad Mini (Apple Inc., Cupertino, CA). The three different head sizes (small, standard, and large) were tested on each patient. A computer-generated algorithm selected at least three high quality cycles to produce an averaged cycle. One of the study investigators (N.P.) with expertise in the arterial hemodynamics and the IF method reviewed all waveforms to confirm the quality of the averaged cycle since the cycle detection algorithm on the application looks for consistency in the pulse waveform data and therefore does not allow for sparse pulse waveform cycle capture. Since small artifacts present in low quality cycles such as tilted or distorted waveforms due to respiration or other motion cause large errors in the calculation of IFs, the investigator (N.P.) further reviewed signals not captured by the computer algorithm while blinded to the patient information and Vivio head size. A recording was considered acceptable if at least one cardiac cycle waveform of high quality could be selected for analysis. The selected cycles were used to compute IFs (ω~1~ and ω~2~). In brief, the IF algorithm computes the two intrinsic frequencies present within a cardiac cycle before and after the closure of the aortic valve, ω~1~ and ω~2~ respectively (see Intrinsic Frequency Method section below).

The three Vivio heads were compared in the age groups \<1, 1--4 (1.0--4.99), 5--9 (5.0--9.99) and 10--14 (10.0--14.99) years of age to see if there was an advantage of using one head size over the other based on age. At least 5 patients were included in each age bracket. The operators spent at least 1 min for data collection. Evaluation of the carotid waveform was significantly limited by patient non-compliance under the age of 5 years old as well as anatomy constraints in the neonates and thus the age groups \<1 and 1--4 years were combined for further analysis. Children 15--19 (15.0--19.99) years old were presumed to be adult-sized and not included in this comparison. The standard head size was used for these patients.

Intrinsic frequency method {#sec006}
--------------------------

The mathematical formulation of the IF method is: $$Minimize:\ \left\| {p\left( t \right) - \chi\left( {0,T_{0}} \right)\left\lbrack \left( a \right._{1}{\cos\left( {\omega_{1}t} \right)} + b_{1}{\sin\left( {\omega_{1}t} \right)} \right\rbrack - \chi\left( {T_{0},T} \right)\left\lbrack \left( a \right._{2}{\cos\left( {\omega_{2}t} \right)} + b_{2}{\sin{\left( {\omega_{2}t} \right)\rbrack}} - c \right.} \right\|_{2}^{2},$$ This L~2~ minimization is subject to continuity at T~0~ and periodicity of the waveform. Here, χ(a,b) is the indicator function (χ(a,b) = 1 if *a*≤*t*≤*b* and χ(a,b) = 0 otherwise), p(t) is the carotid waveform, T is the period of the cardiac cycle, and T~0~ is the left ventricle ejection time. In this study, we corrected ω~1~ and ω~2~ with LV ejection time and heart rate (HR) respectively. IF can be computed using this formula in a fraction of second. Details regarding mathematical formulation of IF method \[[@pone.0227145.ref012]\], its computational procedure \[[@pone.0227145.ref012]\], and its convergence/accuracy \[[@pone.0227145.ref019]\] can be found in previous publications \[[@pone.0227145.ref012], [@pone.0227145.ref017], [@pone.0227145.ref019]\].

Statistical analysis {#sec007}
--------------------

Characteristics of the study population were summarized using standard descriptive measures. ω~1~ and ω~2~ were compared between pediatric age groups 0--4, 5--9, 10--14, and 15--19 years and the adult cohort using a one-way ANOVA with post hoc testing using the Tukey test. Statistical calculations were performed in MATLAB 2018b (Mathworks, Natick, MA). A p-value \< 0.05 was considered statistically significant.

Results {#sec008}
=======

Forty patients were enrolled with a median age of 6.7 years with a range of 0--19.4 years. This included 21 males (52.5%) and 19 females (47.5%). Eleven (27.5%) of these patients were ages \<1 years, 7 (17.5%) were ages 1--4 years, 8 (20%) were ages 5--9 years, 8 (20%) were ages 10--14 years, and 6 (15%) were 15--19 years. Subjects weighed an average of 31.8 kg (2.7--107.9 kg) with an average BMI of 19.4 kg/m^2^ (11.0--36.5 kg/m^2^). All forty patients had structurally normal hearts with normal LV function. Of these patients, in the past, 6 (15%) had received a cardiac transplant and 8 (20%) had received chemotherapy. The complete demographics of the patients enrolled are provided in [Table 1](#pone.0227145.t001){ref-type="table"}. Further breakdown by age is illustrated in [S1 Table](#pone.0227145.s001){ref-type="supplementary-material"} in the supplementary material file. Hemodynamics per pediatric age cohort are shown in [Table 2](#pone.0227145.t002){ref-type="table"}. As expected the average HR decreased while average blood pressure increased with age. Shortening fraction and ejection fraction measured by the modified Simpson's as well as 5/6 area-length methods showed no statistical difference across ages. All patients had normal function by these measures.

10.1371/journal.pone.0227145.t001

###### Demographics.

![](pone.0227145.t001){#pone.0227145.t001g}

  --------------------------------- -----------------------
  Characteristics                   Participants (N = 40)
  **Sex, N (%)**                     
      **Male**                      21 (52.5%)
      **Female**                    19 (47.5%)
  **Race/Ethnicity, N (%)**          
      **Asian/Pacific Islander**    3 (7.5%)
      **Black/African American**    2 (5%)
      **Hispanic**                  21 (52.5%)
      **Non-Hispanic White**        5 (12.5%)
      **Other**                     9 (22.5%)
  **Age at examination, years**      
      **Median, range**             6.7 (0.01--19.4)
  **Age range, N (%)**               
      **\<1**                       11 (27.5%)
      **1--4**                      7 (17.5%)
      **5--9**                      8 (20%)
      **10--14**                    8 (20%)
      **15--19**                    6 (15%)
  **Diagnosis, N (%)**               
      **Normal**                    26 (65%)
      **Post cardiac transplant**   6 (15%)
      **Post chemotherapy**         8 (20%)
  --------------------------------- -----------------------

10.1371/journal.pone.0227145.t002

###### Hemodynamics by pediatric cohort.

![](pone.0227145.t002){#pone.0227145.t002g}

  Age                                                      \<1 Year                 1--4 Years               5--9 Years                 10--14 Years              15--19 Years               
  -------------------------------------------------------- ------------------------ ------------------------ -------------------------- ------------------------- -------------------------- ----------
  **Weight (kg)**                                          5.2 (2.7--7.8, 1.5)      13.1 (8.1--17.1, 2.7)    32.8 (16--78.1, 21.4)      56.1 (30.1--85.9, 16.2)   61.3 (46.4--107.9, 22.5)   p\<0.05
  **Height (cm)**                                          57.5 (48--69.8, 6.5)     91.4 (72--104, 10.4)     123.3 (102.5--154, 18.3)   153 (137--165.4, 9.9)     164.2 (151--179.3, 10.1)   p\<0.05
  **BMI (kg/m2)**                                          15.4 (11--18.2, 2.3)     15.6 (12.7--18.9, 2.0)   19.6 (15.1--32.9, 6.5)     23.8 (15--31.7, 5.9)      25 (18.6--36.5, 6.3)       p\<0.05
  **HR (bpm)**                                             137 (104--158, 16)       109 (88--125, 13)        96 (81--123, 15.8)         91 (71--125, 18.2)        83 (68--95, 12.7)          p\<0.05
  **SBP (mmHg)**                                           91 (60--120, 17.8)       98 (83--110, 11.9)       106 (73--123, 15.3)        114 (100--136, 11.1)      119 (113--127, 5.5)        p\<0.05
  **DBP (mmHg)**                                           59 (40--91, 17.4)        61 (50--76, 8.7)         68 (55--77, 6.5)           66.8 (55--96, 12.8)       67 (58--81, 8.6)           p = 0.5
  **Echo SF (%)**                                          38 (30.4--48.8, 5.5)     36.8 (31.4--40.7, 3.5)   40.8 (37.1--44.7, 2.8)     37.5 (31.4--43.6, 4.3)    37.8 (33.3--42.6, 4.1)     p = 0.43
  **Echo EF (%)** [\*](#t002fn001){ref-type="table-fn"}    61.5 (57.4--65.4, 2.9)   63.1 (57.6--74.5, 6)     62.5 (56.9--71.4, 4.9)     62.9 (55.7--69.5, 4.9)    65.4 (58.5--72, 5.6)       p = 0.66
  **Echo EF (%)**[\*\*](#t002fn002){ref-type="table-fn"}   61.9 (58.2--66.2, 2.9)   63.6 (58.7--68.2, 2.9)   62.4 (57.2--68.8, 4.8)     63.7 (55.2--73.2, 5.9)    65.4 (60--73, 4.7)         p = 0.58

\*Simpson's Method

\*\*5/6 Area-Length Method

The three head sizes were tested in patients under the age of 15 years old. The small head size had weak and over-damped signals which did not allow for analysis of the carotid artery waveform data. Both the standard and large heads demonstrated successful acquisition of carotid waveforms across all age ranges. [Fig 2A](#pone.0227145.g002){ref-type="fig"} displays examples of good quality waveforms from each pediatric age cohort (left: 0--4, middle: 5--9, right: 10--14). [Fig 2B](#pone.0227145.g002){ref-type="fig"} shows examples of averaged cycles from good quality recordings from two patients using both the standard (upper row) and large (lower row) heads. [Fig 2C](#pone.0227145.g002){ref-type="fig"} shows multiple cycle tracings of a good-quality recording in the two different patients using the standard (upper row) and large head (lower row). Comparison of the standard and large head sizes was made across age cohorts 0--4, 5--9, and 10--14 years of age. [Fig 3](#pone.0227145.g003){ref-type="fig"} compares the success rate of capturing an analyzable waveform using the standard vs. large heads, by computer algorithm alone ([Fig 3A](#pone.0227145.g003){ref-type="fig"}) and with expert review ([Fig 3B](#pone.0227145.g003){ref-type="fig"}). Only 3 (17%) of the 18 patients under the age of 5 had analyzable waveforms. Those patients were still and positioned with their heads tilted slightly to the side and upwards to expose the carotid artery better. This improved to 5 patients (28%) after manual evaluation by the expert reviewer. The operator was directed to collect a signal for at least one minute. Among these patients, the standard head worked best in the neonates because the large head size was too large to fit under their chins. In the 5--9 year-old group, 4 (80%) of the 5 patients had signals that were analyzable by the computer algorithm. The fifth patient had an analyzable signal after evaluation by the expert reviewer. This patient had a tracheostomy collar, or breathing tube inserted through a surgically placed hole in the neck, and thus it is likely that the breath sounds from the tracheal collar affected data consistency. 100% of patients in the cohort age 10--14 had signals that were analyzable by the IF algorithm. The standard head was successful in collecting good quality signals in all patients while evaluation by the expert reviewer demonstrated successful signals in all patients with the large head as well. Based on this subgroup analysis, the large head data was used for patients \< 10 years old and the standard head data was used for patients ≥10 years old for group comparisons of ω~1~ and ω~2~ when data were available from both head sizes.

![Examples of carotid waveforms collected by Vivio.\
(A) Examples of waveforms from three different age groups collected by Vivio (left: 0--4, middle: 5--9, right: 10--14). (B) Comparison of waveforms collected by both standard (upper row) and large (lower row) on the same patients (each column is a different patient). (C) Examples of multiple cycle tracings collected by a standard head (top row) and a large head (bottom row) in two different patients. AU is arbitrary unit.](pone.0227145.g002){#pone.0227145.g002}

![Comparison of the standard and large Vivio heads.\
Successful capture of carotid artery waveform as broken down by ages 0--4, 5--9, and 10--14 years as determined by (A) computer algorithm alone and (B) with additional manual review by IF expert.](pone.0227145.g003){#pone.0227145.g003}

The average ω~1~ was 105 +/- 5 bpm and the average ω~2~ was 69 +/- 14 bpm for the entire pediatric cohort. A one-way ANOVA comparison of ω~1~ across the pediatric and adult cohorts demonstrated a significant difference (F = 7.3, Prob\>F = 0.0001). Post-hoc analysis revealed a significant difference between the adult cohort (ω~1~ = 99 +/-5 bpm) and both the 0--4 year old (ω~1~ = 111 +/- 2 bpm; p = 0.0006) and 15--19 year old (ω~1~ = 105 +/- 5 bpm; p = 0.02) cohorts ([Fig 4A](#pone.0227145.g004){ref-type="fig"}). A one-way ANOVA comparison of ω~2~ across all pediatric and adult cohorts showed a significant difference (F = 4.8, Prob\>F = 0.003). Post hoc analysis identified the cohort age 0--4 (ω~2~ = 48 +/- 8 bpm) to be statistically different from the adult cohort (ω~2~ = 82+/- 13 bpm; p = 0.002) ([Fig 4B](#pone.0227145.g004){ref-type="fig"}). [Fig 4C](#pone.0227145.g004){ref-type="fig"} lists the ω~1~ and ω~2~ averages, range and standard error of the mean by age cohort.

![Boxplot analysis of intrinsic frequencies amongst pediatric and adult populations.\
One-way ANOVA was used to compare the intrinsic frequencies of (A) ω~1~ and (B) ω~2~ between ages 0--4, 5--9, 10--14, 15--19, and 20--50 years. (A) There was a significant difference in ω~1~ between the pediatric and adult cohorts (F = 7.3, Prob\>F = 0.0001). Post-hoc analysis demonstrated a significant difference between the adult cohort to both the pediatric cohorts age 0--4 (p = 0.0006) and 15--19 (p = 0.02). (B) There was a significant difference in comparison of ω~2~ (F = 4.8, Prob\>F = 0.003). Post hoc analysis demonstrated that a significant difference between the 0--4 years and age 20--50 years groups (p = 0.002). (C) ω~1~ and ω~2~ averages, range and standard error of the mean by age cohort.](pone.0227145.g004){#pone.0227145.g004}

Discussion {#sec009}
==========

This study demonstrates the feasibility of non-invasive measurement of carotid artery waveforms and evaluating IFs (ω~1~ and ω~2~) in children 5 years of age and older with normal cardiovascular anatomy and LV function using a handheld wireless device, the Vivio. We also showed the difference between IFs values (ω~1~ and ω~2~) of pediatric population and of adults with structurally normal hearts and normal LV function. This is clinically significant since physiologically relevant measures such as LVEF can be approximated from ω~1~ and ω~2~ as shown by Pahlevan et al \[[@pone.0227145.ref017]\] and Armenian et al \[[@pone.0227145.ref018]\]).

Given the wide range of body size in the pediatric population, the sensor head of the Vivio was modified to assess the ease-of-use and hand pressure required to capture non-invasive carotid artery waveforms in pediatric populations. Our results indicated that the small head was not sensitive enough to pick up adequate waveforms for evaluation in any age group. The standard and the large heads successfully captured analyzable waveforms in all age categories. In children under 10 the large head captured a good quality carotid artery signal more frequently than the standard head with the exception of infants aged 0--3 months (neonates). The slight advantage of the larger head in the smaller children is possibly derived from the ability of the large membrane to better amplify the vibratory signal. In neonates, the large head often covered the entire neck leading to significant noise and motion artifact from breathing and oral motion. Additionally, the device hand-grip base length made it difficult to position the head flush on the neck secondary to short neck anatomy without significant repositioning of the neonate which resulted in irritation. In the future, the utility of the Vivio in pediatric population may be enhanced by reducing the length of the body of the Vivio device to better fit the neck space of neonates.

The Vivo successfully captured the carotid artery waveform in all children greater than 5 years of age. The Vivio best captured the carotid artery waveform when the subject held his/her neck in a position to expose the carotid triangle. This was achieved by rotating the head laterally 30--60 degrees and tilting the head up about 30 degrees. Neonates have a characteristically shorter neck in part secondary to a larger head to body ratio and lack of muscle development and thus require a more significant superior tilt of the chin up to 60 degrees to expose the carotid triangle. The Vivio was successful in capturing the carotid artery waveform in children less than 5 years who were able to hold still with their necks in this position without making noise as motion and sound create significant artifact. Methods to achieve this position included placing a neck roll beneath the back in the case of neonates, positioning the child in the parents lap sideways and leaning the head on the parents shoulder, and having the child sit in the parents lap with a video of interest positioned slightly up and to the side to achieve the angle of the neck desired. The device itself was less irritating to younger children than the process of finding the carotid pulse, and so it is possible the success rate may have significantly improved if the operator spent more time (e.g. 5 min) measuring for the waveform after giving the child time to settle. Furthermore, younger children are often fearful of strangers as well as unknown devices, particularly in unfamiliar settings, leading to significant motion artifact. It is likely that with parental training this device can be used by parents with whom the patients are more comfortable or in the setting of sleep at home. Parents were amenable to using the device themselves based on the simple application of the device.

The IF algorithm was used to extrapolate IFs ω~1~ and ω~2~ from the carotid artery waveforms collected by the Vivio. Previous studies have computed IFs among adults with the goal of estimating LVEF using IF ω~1~ and ω~2~ \[[@pone.0227145.ref017], [@pone.0227145.ref018]\]. Since it is difficult to obtain MRI cardiac function data in children (secondary to both cost and possible need for anesthesia in this population), IF evaluation by Vivio holds significant promise for a quick and easy method of accurately measuring LVEF in pediatrics. This study shows no statistical difference between pediatric cohorts for IF ω~1~ and ω~2~; however, there was a statistical difference between cohort age 0--4 years and the adult population in both ω~1~ and ω~2~. There was also a statistical difference in ω~1~ between the adult population and cohort age 15--19 years. These differences may, particularly in the cohort age 0--4 years, be secondary to the low number of successfully captured waveforms. It is important to note that removal of the cohort age 0--4 may change the statistical significance of ω~1~ and ω~2~ particularly with larger cohort sizes; however, given the great need for a better method to measure LVEF in this population these data were included in analysis. It will be important to reanalyze this age group in the future after modifications are made to allow for effective use of the device in this age group. A limitation of this study overall is the low number of patients enrolled and so future studies with larger patient enrollment will be important to verify the lack of difference seen between the pediatric cohorts in addition to the difference seen in specific pediatric cohorts in comparison to the adult population. The equation that computes LVEF from IFs in adults is a function of ω~1~ and also depends on ω~2~ \[[@pone.0227145.ref017], [@pone.0227145.ref018]\]. This study suggests that the normal range of ω~1~ and ω~2~ among pediatrics is different from adults. This is expected since cardiovascular dynamics in pediatrics is different than in adults (e.g. different HRs and different blood distribution to upper/lower body). This study was limited to patients with normal LV function. Further studies will be required to enroll patients with various stages of heart failure and a wide range of LVEF in order deduce an equation to calculate LVEF using IFs in the pediatric population similar to the study performed by Pahlevan *et al* \[[@pone.0227145.ref017]\].

Conclusion {#sec010}
==========

This study demonstrates the proof-of-concept that the Vivio can be used to successfully measure the carotid artery waveform for evaluation of cardiovascular intrinsic frequencies (IFs) in children 5 years of age and older. Our results showed a statistically significant difference in IF ω~1~ and ω~2~ between children and adult populations suggesting that further studies are required to derive an equation relating IFs to LVEF in the pediatric population. Parental training for data collection or creation of a hands-free version of the Vivio could significantly improve the utility of the Vivio in pediatric patients especially among patients under the age of 5 years. Overall, this study suggests that Vivio (a non-invasive, portable, and smartphone-based device) has the potential for cardiovascular monitoring in pediatric patients in an at home environment.

Supporting information {#sec011}
======================

###### Breakdown of physiology by pediatric cohort.

Number of patients with each type of physiology by age group.

(TIFF)

###### 

Click here for additional data file.
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We look forward to receiving your revised manuscript.

Best regards,

John Lynn Jefferies, MD MPH FACC FAHA

Academic Editor

PLOS ONE

**Journal Requirements:**

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2.  Thank you for including your ethics statement:  \"This study was approved by the CHLA IRB CHLA-17-00377. Consent/assent was obtained verbally form the participant and/or their parent as appropriate.\".

a.Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

b.Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to <http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research>.

3.  Thank you for stating in your Funding Statement:

\"N.P.: This study was partially funded by Atlantic Pediatric Device Consortium (APDC) Subaward No. RG219-G6 <http://atlanticpediatricdeviceconsortium.org/>

The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

Please provide an amended statement that declares \*all\* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at [http://journals.plos.org/plosone/s/submit-now. ](http://journals.plos.org/plosone/s/submit-now. ) Please also include the statement "There was no additional external funding received for this study." in your updated Funding Statement.

Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.

4\. Thank you for stating the following in the Competing Interests section:

\"Niema M. Pahlevan hold equity in Avicena LLC  and has consulting agreement with Avicena LLC.

Derek Rinderknecht is the Chief Technical Officer of Avicena, LLC, the manufacturer of the Vivio and owns equity stake in the company.\"

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The concept, study design, analysis, and interpretation seem appropriate. There are no ethical concerns. A further discussion of the challenges with the device in younger children would be helpful to the reader.

Reviewer \#2: This article reports on the feasibility of the use of a non-invasive, portable cardiovascular monitoring system, the Vivio in pediatric patients.

METHODS: For the age groupings do the authors actually mean 1-4, 5-9, 10-15, 16-20? There seemed to be overlap in the age groups 1-5, 5-10, 10-15, 15-20 in some places and \>15 in others, 16-20. However, both probes appear to have been used in the 15 and under, but only the standard adult probe in the 16 and older group. Please clarify, otherwise it appears that some ages are double counted and "groupings" seem off.

RESULTS: Despite finding statistically significant differences between children and adults the numbers in each pediatric group are quite small, especially in the less than 5 age group, in which only 3-5 patients had an analyzable wave forms. I am not sure the frequency data (IF) from the Vivio should even be reported for the less than 5 age group, with larger numbers statistical significance could actually be lost.

Page 12, line 237: The part of the sentence that states: the success rate may have significantly improved....this should be deleted from results and only be in the discussion section.

DISCUSSION: On page 14 line 281 add: in children older than 5 years, the feasibility is not really proven for the younger set.

On page 15 lines 303-305: This is new information about the data being capturable in those less than 5 who held still or had their heads tilted. This should somehow be incorporated into the results when the data collection on this age group is reported. (I take it these were the 3-5 who had interpretable data)

On page 16 lines 314-315: Lack of differences between the pediatric cohorts for IF's could also be due to numbers.

On page 16, lines 321- 323: This study "suggests" not "demonstrates," as it seems the differences were due to the youngest and oldest nonadult age group which seems odd.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0227145.r002

Author response to Decision Letter 0

20 Nov 2019

We thank our reviewers for the positive evaluations and constructive suggestions. Our manuscript has been greatly improved with the reviewers' help. Below we list our responses in the sequence in which they were raised in each reviewer's report. These responses are included in the Response to Reviewers document as well.

Comments to the Author

Reviewer 1:

Comment 1: A further discussion of the challenges with the device in younger children would be helpful to the reader.

Response:

Thank you for your review and the thoughtful comments. We have revised the Discussion in the manuscript as follows to further discuss the challenges of the device in younger children.

"The Vivio successfully captured the carotid artery waveform in all children greater than 5 years of age. The Vivio best captured the carotid artery waveform when the subject held his/her neck in a position to expose the carotid triangle. This was achieved by rotating the head laterally 30-60 degrees and tilting the head up about 30 degrees. Neonates have a characteristically shorter neck in part secondary to a larger head to body ratio and lack of muscle development, and thus require a more significant superior tilt of the chin up to 60 degrees to expose the carotid triangle. The Vivio was successful in capturing the carotid artery waveform in children less than 5 years who were able to hold still with their necks in this position without making noise, as motion and sound create significant artifact. Methods to achieve this position included placing a neck roll beneath the back in the case of neonates, positioning the child in the parents lap sideways and leaning the head on the parent's shoulder, and having the child sit in the parent's lap with a video of interest positioned slightly up and to the side to achieve the angle of the neck desired. The device itself was less irritating to younger children than the process of finding the carotid pulse, and so it is possible the success rate may have significantly improved if the operator spent more time (e.g. 5 min) measuring for the waveform after giving the child time to settle. Furthermore, younger children are often fearful of strangers as well as unknown devices, particularly in unfamiliar settings, leading to significant motion artifact. It is likely that with parental training this device can be used by parents with whom the patients are more comfortable or in the setting of sleep at home. Parents were amenable to using the device themselves based on the simple application of the device."

Reviewer 2:

Comment 1a: METHODS: For the age groupings do the authors actually mean 1-4, 5-9, 10-15, 16-20? There seemed to be overlap in the age groups 1-5, 5-10, 10-15, 15-20 in some places and \>15 in others, 16-20.

Response:

We would like to thank the reviewer for this constructive comment. We have changed the group labels to \<1, 1-4, 5-9, 10-14, and 15-19. These adjustments were made throughout in the document, tables, and figures as necessary. For further clarification, in the Methods we stated that we enrolled patients 0-19.9 years old and additionally defined age groups as follows so there would be no confusion about age cut offs:

"The three Vivio heads were compared in the age groups \<1, 1-4 (1.0-4.99), 5-9 (5.0-9.99) and 10-14 (10.0-14.99) years of age to see if there was an advantage of using one head size over the other based on age." . . . . "Children 15 -- 19 (15.0-19.99) years old were presumed to be adult-sized and not included in this comparison. The standard head size was used for these patients"

In the Results section we included:

"Forty patients were enrolled with a median age of 6.7 years with a range of 0-19.4 years."

Comment 1b: However, both probes appear to have been used in the 15 and under, but only the standard adult probe in the 16 and older group. Please clarify, otherwise it appears that some ages are double counted and "groupings" seem off.

Response:

In the original analysis, we included one patient age 15.4 years old in the comparison of the 3 head sizes. For this reason, we stated we only used the standard probe in patients 16 and older. Removing this patient does not alter our overall conclusion that there was successful capture of analyzable waveform in all patients age 10-14. We thus removed this patient and recreated the Fig 3 in order to keep consistent age cohorts throughout the paper to minimize confusion. Removal of the 15.4 year-old patient resulted in all patients with computer analyzable signals using both medium and large heads. This adjustment was made to Fig 3a. There were no changes to Fig 3b.

In making this edit, we noted that Fig 3 was created based on the original and not final computer averaged data set. The final computer averaged data set used for analysis in the rest of the paper was able to measure a waveform using both the standard and large head in a patient previously only noted have a wave form measured in the large head in the age group 5-9 years. This adjustment was made in Fig 3a. There was no difference in Fig 3b or to the conclusion described in the paper that only 80% of patients had signals that were analyzable by computer algorithm alone.

Comment 2: RESULTS: Despite finding statistically significant differences between children and adults the numbers in each pediatric group are quite small, especially in the less than 5 age group, in which only 3-5 patients had an analyzable wave forms. I am not sure the frequency data (IF) from the Vivio should even be reported for the less than 5 age group, with larger numbers statistical significance could actually be lost.

Response:

We would like to thank the reviewer for this constructive comment. When the less than 5 years of age group is removed, there is a significant difference in ω1 between the pediatric and adults cohorts (prob\>F 0.0027). Post-hoc analysis demonstrates the difference is between the adult and age 15-19 cohort (p=0.003). Thus, removal of the age cohort 0-4 does not change the conclusion in regards to ω1 and we will need to further data in the future to deduce an equation for LVEF. Removal of the age group less than 5 years of age shows that there is not a significant difference in ω2 between the adult and pediatric cohorts (prob\>F 0.16). This is in line with the subgroup analysis provided in the paper that demonstrates a significant difference only between the age cohorts 0-4 and the adult population. We agree that keeping this population in our analysis has the possibility to alter the results of ω2; however, given that there is still a difference in ω1 and the fact that this population in particular is in need of a better method for measuring LVEF, we feel it is important to include the age cohort in our analysis. We have modified our discussion to address the reviewers concern as follows:

"It is important to note that removal of the cohort age 0-4 may change the statistical significance of ω1 and ω2 particularly with larger cohort sizes; however, given the great need for a better method to measure LVEF in this population these data were included in analysis"

Comment 3: Page 12, line 237: The part of the sentence that states: the success rate may have significantly improved....this should be deleted from results and only be in the discussion section.

Response:

Thank you for the recommended revision. We revised the manuscript as recommended. The sentence was deleted from the results and added to discussion.

"The device itself was less irritating to younger children then the process of finding the carotid pulse, and so it is possible the success rate may have significantly improved if the operator spent more time (e.g. 5 min) measuring for the waveform after giving the child time to settle"

Comment 4: On page 14 line 281 add: in children older than 5 years, the feasibility is not really proven for the younger set.

Response:

Thank you for the recommended revision. We have revised the manuscript to include the phrase "in children 5 years of age and older"

Comment 5: On page 15 lines 303-305: This is new information about the data being capturable in those less than 5 who held still or had their heads tilted. This should somehow be incorporated into the results when the data collection on this age group is reported. (I take it these were the 3-5 who had interpretable data)

Response:

Thank you for the recommended revision. We have revised the results section of the manuscript to include the sentence "Those patients were still and positioned with their heads tilted slightly to the side and upwards to expose the carotid artery better."

Comment 6: On page 16 lines 314-315: Lack of differences between the pediatric cohorts for IF's could also be due to numbers.

Response:

Thank you for the constructive comment. We agree with the reviewer's comment that this is an important limitation. We have revised the discussion section of the manuscript to include the following statements in order to address the comments provided:

"A limitation of this study overall is the low number of patients enrolled and so future studies with larger patient enrollment will be important to verify the lack of difference seen between the pediatric cohorts in addition to the difference seen in specific pediatric cohorts in comparison to the adult population."

Comment 7: On page 16, lines 321- 323: This study "suggests" not "demonstrates," as it seems the differences were due to the youngest and oldest nonadult age group which seems odd.

Response:

We have revised the manuscript as requested.

Additional response to editor: Table 2 was not introduced in the text of the body. We added the following sentence to the results section to address this issue:

"Hemodynamics per pediatric age cohort are shown in Table 2."
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Click here for additional data file.

10.1371/journal.pone.0227145.r003

Decision Letter 1

Jefferies

John Lynn

Academic Editor

© 2019 John Lynn Jefferies

2019

John Lynn Jefferies

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

4 Dec 2019

PONE-D-19-22751R1

Proof-Of-Concept For A Non-invasive, Portable, and Wireless Device for Cardiovascular Monitoring in Pediatric Patients

PLOS ONE

Dear Dr. Miller,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jan 18 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

John Lynn Jefferies, MD, MPH, FACC, FAHA

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors responded adequately to the reviewers\' comments. The study provides important new insights.

Reviewer \#2: The issues that I had previously brought up have been addressed within the limitations of the study.

I have a couple of new comments.

Under study participants post transplant patients n=5 and post chemotherapy patients n=9. However in the results section post transpalnt n=6 and post chemo n=8 in the text and Table 1. Please reconcile.

Page 13 line 260: I think the authors mean B not A when referring to figure 3. \"A\" is used twice.

The authors report that after manual review some additional waveforms could be added for assessment that the computer algorithm misclassified as not usuable. Were there any reversed by manual review, meaning the computer algorithm said the waveforms were usable but the manual reviewer felt they actually were not usable?

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0227145.r004

Author response to Decision Letter 1

9 Dec 2019

We thank our editor and reviewers for the positive evaluations and constructive suggestions. Our manuscript has been greatly improved with the reviewers' help. Below we list our responses in the sequence in which they were raised in each reviewer's report.

Comments to the Author

Reviewer \#1: The authors responded adequately to the reviewers\' comments. The study provides important new insights.

Response:

We thank the author for their response

Reviewer \#2:

Comment 1: The issues that I had previously brought up have been addressed within the limitations of the study. I have a couple of new comments.

Under study participants post transplant patients n=5 and post chemotherapy patients n=9. However in the results section post transpalnt n=6 and post chemo n=8 in the text and Table 1. Please reconcile.

Response:

We would like to thank the reviewer for this constructive comment. We have revised the section study participants to match the results section. Sup Fig 1 was also reconciled. The table and results discussion were reviewed and are correct.

Comment 2: Page 13 line 260: I think the authors mean B not A when referring to figure 3. \"A\" is used twice.

Response:

We thank the reviewer for their careful review. We revised the manuscript as recommended and changed the Fig 3 legend to list A and B.

Comment 3: The authors report that after manual review some additional waveforms could be added for assessment that the computer algorithm misclassified as not usuable. Were there any reversed by manual review, meaning the computer algorithm

Response:

We would like to thank the reviewer for this question. The automatic computer algorithm looks at the consistency of the recordings. For example, if there are 1-2 appropriate waveforms interspaced with poor recordings the algorithm will not capture them; however, a waveform expert can easily identify the good cycles in this situation. The reverse is highly unlikely. No computer identified recordings were later deemed by the expert reviewer to be inaccurate in this paper.
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PONE-D-19-22751R2

Dear Dr. Miller,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Best regards,

John Lynn Jefferies, MD MPH FACC FAHA

Academic Editor

PLOS ONE
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PONE-D-19-22751R2

Proof-Of-Concept For A Non-invasive, Portable, and Wireless Device for Cardiovascular Monitoring in Pediatric Patients

Dear Dr. Miller:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. John Lynn Jefferies

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**Niema M. Pahlevan hold equity in Avicena LLC and has consulting agreement with Avicena LLC. Derek Rinderknecht is the Chief Technical Officer of Avicena, LLC, the manufacturer of the Vivio and owns equity stake in the company. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
